Rad23A Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
:: infobox .infobox-protein
| Protein Name | RAD23 Homolog A (RAD23A) |
| Gene | RAD23A |
| UniProt | P49411 |
| PDB Structure | 1T5L, 2JSS |
| Molecular Weight | ~40 kDa |
| Subcellular Localization | Nucleus |
| Protein Family | RAD23 family |
::
RAD23 Homolog A (RAD23A) is a bifunctional protein involved in both nucleotide excision repair (NER) and the ubiquitin-proteasome system. It serves as a molecular adaptor that bridges DNA damage recognition proteins with the NER machinery and delivers polyubiquitinated substrates to the proteasome for degradation. RAD23A is highly expressed in neuronal tissues, where its dual roles in DNA repair and protein quality control are particularly important for maintaining neuronal health.
RAD23A is a 362-amino acid protein with multiple functional domains. It contains an N-terminal ubiquitin-like (Ubl) domain that interacts with the proteasome, and two C-terminal ubiquitin-binding (UBA) domains that bind polyubiquitinated proteins. RAD23A also has an XPC-binding domain that recruits it to DNA damage sites.
RAD23A has dual functions in nucleotide excision repair (NER) and the ubiquitin-proteasome system. As an XPC cofactor, RAD23A helps recruit the TFIIH complex to DNA damage sites for NER. As a proteasome-interacting protein, it helps deliver ubiquitinated substrates for degradation.
In neurons, RAD23A's roles in DNA repair and protein quality control are both critical. Neuronal protein aggregates and DNA damage accumulate with age, potentially overwhelming these systems.
RAD23A helps clear damaged proteins via the proteasome. Impaired function may contribute to amyloid-beta and tau aggregation in AD.
RAD23A-mediated protein quality control may be relevant to alpha-synuclein clearance. Impaired proteasome function is a feature of PD pathogenesis.
No RAD23A-targeted therapies exist. Enhancing proteasome function is a therapeutic strategy being explored for neurodegenerative diseases.
The study of Rad23A Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.